Contact: Sandra Menta (US) Anne Marie Rodriguez (Europe) Cephalon, Inc. Sante Communications 610-738-
FOR IMMEDIATE RELEASE
Cephalon Receives Authorization to Market PROVIGIL(R) (modafinil) in the Republic of Ireland
WEST CHESTER, PA -- May 15, 1998 -- Cephalon, Inc. (NASDAQ: CEPH) announced today that its UK
subsidiary, Cephalon UK Ltd., has received authorization from the Irish Medicines Board (IMB) to market
PROVIGIL(R) (modafinil) tablets in the Republic of Ireland for the treatment of narcolepsy.
Narcolepsy is a chronic, neurological, lifelong sleep disorder that generally begins in young adulthood. The most
common symptom is excessive daytime sleepiness, which is characterized by uncontrollable sleep attacks. These
attacks hamper a person's ability to perform basic daily activities. As a result, narcolepsy significantly impacts a
person's quality of life.
Cephalon intends to manufacture PROVIGIL tablets in the United States and launch the drug in the Republic of
Ireland upon IMB approval of the U.S. manufacturing arrangements.
"This is the first non-amphetamine agent licensed for the treatment of narcolepsy in Ireland," said Frank Baldino,
Jr., Ph.D., Cephalon's president and chief executive officer. "Our European sales and marketing organization look
forward to making PROVIGIL available to the neurology community in Ireland for patients suffering from this
Cephalon licensed modafinil from Laboratoire L. Lafon, the French pharmaceutical company which discovered
and markets the drug in France. Cephalon has exclusive rights to market modafinil in the United States, Japan,
the United Kingdom, Ireland, Mexico and Italy. In March 1998, Cephalon commenced marketing of PROVIGIL
in the United Kingdom. Cephalon has a marketing application currently pending in the United States to market
PROVIGIL for the treatment of excessive daytime sleepiness associated with narcolepsy.
- continued -
Cephalon Receives Authorization